Combining the results of network pharmacology with other bioinformatics databases suggests that myrrh’s active components exert anti-cancer effects by regulating genes involved in breast cancer pathogenesis, particularly PTGS2, EGFR, ESR2, MMP2, and JUN. The gene discussed is ESR2; the disease is breast carcinoma.